BioCryst (BCRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from H.C. Wainwright reiterated a Buy rating on the stock and has a $30.00 price target.
Andrew Fein has given his Buy rating due to a combination of factors related to BioCryst’s promising pipeline and strong market position. One of the key reasons is the potential of BCX17725, a KLK5 inhibitor, which is being developed for Netherton Syndrome, a rare genetic skin condition. This drug represents a significant opportunity as it targets the underlying cause of the disease, potentially offering a disease-modifying treatment where none currently exists. With an estimated patient population of 1,600 in the U.S., and potentially more if an approved therapy becomes available, BCX17725 could address a substantial unmet need.
Additionally, Andrew Fein is optimistic about the continued growth of Orladeyo, BioCryst’s treatment for hereditary angioedema (HAE). Despite a competitive market, Orladeyo has demonstrated significant efficacy and convenience, leading to a 37% year-over-year increase in revenue for the fourth quarter of 2024. The recent adjustments in revenue guidance for 2025, driven by favorable impacts from the Inflation Reduction Act for Medicare patients, further support the Buy rating. These factors combined underscore the potential for BioCryst to achieve sustained growth and success in the rare disease market.
In another report released today, JMP Securities also maintained a Buy rating on the stock with a $18.00 price target.